- Home
- CLFD vs TSHA Comparison
CLFD vs TSHA Comparison
Compare CLFD & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLFD
- TSHA
- Stock Information
- Founded
- CLFD 1979
- TSHA 2019
- Country
- CLFD United States
- TSHA United States
- Employees
- CLFD N/A
- TSHA N/A
- Industry
- CLFD Telecommunications Equipment
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- CLFD Utilities
- TSHA Health Care
- Exchange
- CLFD Nasdaq
- TSHA Nasdaq
- Market Cap
- CLFD 426.1M
- TSHA 397.8M
- IPO Year
- CLFD N/A
- TSHA 2020
- Fundamental
- Price
- CLFD $37.11
- TSHA $2.71
- Analyst Decision
- CLFD Strong Buy
- TSHA Strong Buy
- Analyst Count
- CLFD 3
- TSHA 7
- Target Price
- CLFD $46.67
- TSHA $7.00
- AVG Volume (30 Days)
- CLFD 185.2K
- TSHA 5.2M
- Earning Date
- CLFD 05-08-2025
- TSHA 05-15-2025
- Dividend Yield
- CLFD N/A
- TSHA N/A
- EPS Growth
- CLFD N/A
- TSHA N/A
- EPS
- CLFD N/A
- TSHA N/A
- Revenue
- CLFD $178,209,000.00
- TSHA $7,224,000.00
- Revenue This Year
- CLFD $10.77
- TSHA N/A
- Revenue Next Year
- CLFD $14.46
- TSHA N/A
- P/E Ratio
- CLFD N/A
- TSHA N/A
- Revenue Growth
- CLFD N/A
- TSHA N/A
- 52 Week Low
- CLFD $23.78
- TSHA $1.05
- 52 Week High
- CLFD $44.83
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- CLFD 61.72
- TSHA 60.38
- Support Level
- CLFD $37.49
- TSHA $2.44
- Resistance Level
- CLFD $38.98
- TSHA $2.95
- Average True Range (ATR)
- CLFD 1.52
- TSHA 0.25
- MACD
- CLFD -0.21
- TSHA -0.02
- Stochastic Oscillator
- CLFD 56.54
- TSHA 51.60
About CLFD Clearfield Inc.
Clearfield Inc mainly designs, manufactures, and distributes fiber protection, fiber management and fiber delivery solutions for communications networks. It provides a range of products including copper assemblies, cassettes, box enclosures, fiber connectors, frames, microduct, terminals, vaults, pedestal inserts, FieldSmart, WaveSmart, and CraftSmart. The company has a global presence with the majority of the revenue derived from the United States. The company has two reportable segments namely Clearfield segment and Nestor cables segment. The majority of revenue is derived from Clearfield segment.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.